What question did this study set out to answer?

To provide evidence-informed guidelines for the use of peptide receptor radionuclide therapy (PRRT) in treating neuroendocrine tumors (NETs).

March 13, 2026Open Access

Recommendations for selection, treatment, and follow-up in peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors: a Delphi consensus from the Galician Multidisciplinary Group on Neuroendocrine and Endocrine Tumors (GGNET)

Key Points

To provide evidence-informed guidelines for the use of peptide receptor radionuclide therapy (PRRT) in treating neuroendocrine tumors (NETs).
Conducted a Delphi consensus with multidisciplinary experts in neuroendocrine tumors.
Developed evidence-informed statements to guide clinical practice.
Created an algorithm for treatment selection and follow-up.
Guidelines aim to standardize PRRT practices across various treatment centers.
Expected to reduce care variability and enhance patient safety.
Ultimately aims to improve treatment outcomes for patients with NETs.

Abstract

This Delphi consensus provides pragmatic, multidisciplinary, and evidence-informed guidance to harmonize routine clinical practice in the use of PRRT for well-differentiated, SSTR-positive NETs. The proposed statements and the algorithm aim to harmonize practice across centers, reduce variability in care, enhance safety, and ultimately improve patient outcomes.

Demander à l'IA

Bookmark

View Full Paper